Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875610 | 0.88 | NOTUM (0.46) | GAAKDM4EKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1887533 | 0.85 | MAPK8 (0.50) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL1880517 | 0.84 | MAPT (0.47) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL1890367 | 0.84 | GAA (0.48) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL12672070 | 0.84 | GAA (0.44) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL1878254 | 0.81 | MAPT (0.42) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL1877442 | 0.79 | MAPT (0.49) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL1875614 | 0.79 | GAA (0.60) | MAPTTHRBGAANPSR1L3MBTL1 | |
| SCHEMBL1883652 | 0.79 | S1PR3 (0.57) | — | |
| SCHEMBL1884573 | 0.72 | NOTUM (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | ALLERGAN, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| EP-2185506-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009026407-A1 | PYRROLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105567-A1 | Pyrrole Compounds Having Sphingosine-1-Phosphate Receptor Agonist Or Antagonist Biological Activity | S1PR1, S1PR2, S1PR3 | MAPT 3241/4885THRB 455/4885GAA 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.